NCT00002055已完成不适用
A Double-Blind Group Comparative Study To Evaluate the Long-Term Safety and Effectiveness of Two Different Doses of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients With Multiple Episodes of PCP
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Fisons
- 试验地点
- 8
研究概览
简要总结
To evaluate and compare the safety, tolerability, and effectiveness of long-term biweekly administration of 1 of 2 doses of aerosol pentamidine when used as a prophylactic agent in patients who have had multiple episodes of AIDS associated Pneumocystis carinii pneumonia (PCP).
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Zidovudine (AZT).
- •Patients must have:
- •Recovered from their most recent episode of Pneumocystis carinii pneumonia (PCP). Patients must be at least 2 weeks status post therapy for acute PCP.
- •Adequate pulmonary function (vital capacity = or > 65 percent of predicted; forced expiratory volume, 1 s = or > 55 percent of total FEV; and corrected pulmonary diffusion capacity > 50 percent of predicted).
- •Patients must be free of acute medical problems.
排除标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •AIDS-defining opportunistic infection prior to entry such as toxoplasmosis and cryptococcosis.
- •Pulmonary Kaposi's sarcoma.
- •Asthma poorly controlled by medication.
- •Receiving active therapy for tuberculosis.
- •Concurrent Medication:
- •Active therapy for tuberculosis.
- •Patients with the following are excluded:
- •Requiring ongoing active therapy for an opportunistic infection at time of study entry.
- •AIDS-defining opportunistic infection prior to study entry such as toxoplasmosis and cryptococcosis.
- •Pulmonary Kaposi's sarcoma.
- •Unwilling to sign informed consent.
- •Asthma poorly controlled by medication.
- •Unwilling to cooperate with study procedures.
- •Receiving active therapy for tuberculosis.
- •Prior Medication:
- •Excluded within 30 days of study entry:
- •Antiretrovirals (other than zidovudine (AZT)).
- •Immunomodulating agents.
- •Corticosteroids.
- •Prior Treatment:
- •Excluded within 7 days of study entry:
- •Transfusion.
- •Patient cannot be transfusion dependent (requiring blood transfusion more than once per month).
- •Active substance abuse.
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
The Safety and Effectiveness of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Who Have Had PCP BeforePneumonia, Pneumocystis CariniiHIV InfectionsNCT00002291Fisons
已完成
3 期
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01431287Boehringer Ingelheim2,539
已完成
3 期
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)Pulmonary Disease, Chronic ObstructiveNCT01431274Boehringer Ingelheim2,624
已完成
3 期
Japan Long-term Safety for Tiotropium Plus OlodaterolPulmonary Disease, Chronic ObstructiveNCT01536262Boehringer Ingelheim122
终止
3 期
Carisbamate Retention Study (CaReS): Comparative Study on the Long Term Effectiveness, Safety and Tolerability of Carisbamate Compared to Two Other Frequently Prescribed Anti-epileptic Drugs (AEDs) in Patients With Epilepsy.SeizuresEpilepsyNCT00563459SK Life Science, Inc.89